British drugmaker Shire Plc (SHP.L) would like to acquire experimental products derived from stem cells, but the company’s chief executive said it is hard to find assets that are likely to make money.
Speaking at the Reuters Health Summit on Wednesday, Angus Russell said the two areas of medicine that will be “transformational” are stem cells and genetics.
Both technologies hold the potential to help the body’s cells and tissue regenerate and fight diseases ranging from diabetes to Alzheimer’s.
